Abstract: The present invention relates to the use of a novel Lactobacillus brevis ProGA28 strain, deposited in the German Collection for Microorganisms and Cell Cultures (DSMZ) under the accession number DSM 33167 on May 28, 2019. The metabolites of Lactobacillus brevis ProGA28 have the ability to improve sleep quality, can effectively reduce the time of rapid eye movement in the sleep phase, can reduce time to fall asleep, can increase total sleep time, and can increase the ratio of low waves during sleep so that sleep disorders and related complications, such as anxiety and immune system diseases, are treated.

Abstract: The present invention discloses a novel Lactobacillus brevis ProGA28, deposited in the German Collection for Microorganisms and Cell Cultures, the accession number is DSM 33167, and the deposit date is on 28 May, 2019. The metabolites of the novel Lactobacillus brevis ProGA28 has the ability to improve sleep quality, and can effectively reduce the time of rapid eye movement in sleep phase, reduce the number of falling asleep, increase the total sleep time, prolong the time of single falling asleep, and increase the ratio of low waves during sleep, so that it can achieve the effect of treating or improving sleep disorders and related complications, such as anxiety and immune system diseases.